With increasing accuracy of biomarkers has come the ability to identify groups of individuals at risk for PD and DLB or who are prodromal [7–9]—that is, those who have mild signs or symptoms within the continuum of Lewy body disorders (LBD) due to underlying neuronal α-synuclein (asyn) pathology. This evidence concerns the gene SNCA and Lewy body dementia.